Industry Insight
Information, Observation & Analysis
Therapeutics Articles
Immune globulin replacement and prophylactic antibiotics are commonly used to prevent infections in patients with secondary hypogammaglobulinemia due to hematological malignancies but have never been directly compared.
While neutropenia can be a life-threatening condition, physicians have many tools to treat it.
A new vaccine currently in development can effectively and affordably lower levels of “bad’ cholesterol in the body, a health problem that affects almost two in five adults in the U.S.
The U.S. Food and Drug Administration has approved two treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older.
CSL Behring is discontinuing all sizes of Hizentra vials in the U.S. by the end of September 2024.
Numerous studies show the efficacy of both IVIG and SCIG for treating CIDP, making these the best treatment options for this rare neurological condition.
The effectiveness of this controversial therapy in treating musculoskeletal disorders and other arthritic conditions is uncertain due to mixed results. Nevertheless, the PRP industry is booming.
It is now well-established that prehospital transfusion of plasma, with its balanced mix of coagulation proteins, counters the hemodilution and progressive derangement of hemostatic mechanisms caused by crystalloid-based resuscitation, improving the changes of survival in severely bleed trauma victims.
In the realm of healthcare and pharmaceuticals, orphan drugs have emerged as a beacon of hope for individuals suffering from rare diseases. With new technology and AI-driven analytics as drivers, these once-niche therapies are rapidly taking center stage.
Precise, personal treatment is the way of the future. Here's how experts are using genetic sequencing to forge a revolutionary new way of practicing medicine.
Renewed interest and research in psychedelic compounds is giving formerly illicit drugs a 21st century image makeover. Are they really breakthrough solutions for treatment-resistant conditions such as depression and PTSD? At this point, the data looks promising.
For decades, respiratory syncytial virus (RSV) has defied the best efforts of vaccine makers to bring it to heel, until now.